- Home
- VYGR
as 03-28-2025 4:00pm EST
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.
| Founded: | 2013 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 222.9M | IPO Year: | 2015 |
| Target Price: | $14.86 | AVG Volume (30 days): | 356.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.13 | EPS Growth: | N/A |
| 52 Week Low/High: | $3.56 - $10.66 | Next Earning Date: | 03-11-2025 |
| Revenue: | $80,001,000 | Revenue Growth: | -68.00% |
| Revenue Growth (this year): | -13% | Revenue Growth (next year): | 23.46% |
Stock Insider Trading Activity of Voyager Therapeutics Inc. (VYGR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Sandrock Alfred | VYGR | President and CEO | Feb 20 '25 | Sell | $4.24 | 11,702 | $49,616.48 | 296,816 | |
| Swartz Robin | VYGR | COO & CBO | Feb 20 '25 | Sell | $4.25 | 3,894 | $16,549.50 | 98,397 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 20 '25 | Sell | $4.26 | 3,305 | $14,079.30 | 77,718 | |
| Sandrock Alfred | VYGR | President & CEO | Feb 11 '25 | Sell | $4.45 | 16,644 | $74,065.80 | 296,816 | |
| Fahey Sandell Jacquelyn | VYGR | Chief Legal Officer | Feb 11 '25 | Sell | $4.45 | 4,358 | $19,393.10 | 81,643 | |
| Swartz Robin | VYGR | COO & CBO | Feb 11 '25 | Sell | $4.45 | 6,950 | $30,927.50 | 98,397 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Feb 11 '25 | Sell | $4.45 | 5,413 | $24,087.85 | 77,718 | |
| Swartz Robin | VYGR | COO & CBO | Jan 14 '25 | Sell | $5.09 | 3,087 | $15,712.83 | 98,397 | |
| Carter Todd Alfred | VYGR | Chief Scientific Officer | Jan 14 '25 | Sell | $5.13 | 1,191 | $6,109.83 | 77,718 |
Latest Voyager Therapeutics Inc. News
VYGR Breaking Stock News: Dive into VYGR Ticker-Specific Updates for Smart Investing
Thomson Reuters StreetEvents
17 days ago
Q4 2024 Voyager Therapeutics Inc Earnings Call
Zacks
17 days ago
Voyager Therapeutics (VYGR) Reports Q4 Loss, Misses Revenue Estimates
Associated Press Finance
17 days ago
Voyager Therapeutics: Q4 Earnings Snapshot
GlobeNewswire
17 days ago
Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results
GlobeNewswire
25 days ago
Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast
Pharma Voice
25 days ago
New tau candidates, including an RNA therapy from Voyager, drive a multi-pronged Alzheimer’s approach
MT Newswires
a month ago
Voyager Therapeutics Reports Positive Trial Results From Alzheimer's Disease Treatment
GlobeNewswire
a month ago
Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease
Compare VYGR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VYGR Voyager Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.